Risk of long QT syndrome in novel coronavirus COVID-19
- Authors: Oslopov VN1, Oslopova JV2, Hazova EV1, Sergienko KS1, Murzakhanova AF1, Boichuk JM1
-
Affiliations:
- Kazan State Medical University
- Kazan (Volga Region) Federal University
- Issue: Vol 101, No 5 (2020)
- Pages: 749-753
- Section: Clinical experiences
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/43119
- DOI: https://doi.org/10.17816/KMJ2020-749
- ID: 43119
Cite item
Open Access
Access granted
Abstract
The article is devoted to the risk of cardiovascular disease in coronavirus infection. In March 2020, the World Health Organization announced the COVID-19 pandemic. The virus set many tasks for practicing doctors, including the study of its pathogenesis and the creation of a therapy suitable for all patient groups. This paper presents information about cellular entry of the coronavirus, the development of cardiovascular diseases, in particular, the heart, and the latest data on experimental therapy with hydroxychloroquine. Coronavirus has been shown to affect the synthesis of angiotensin 2, which increase the QT interval. At the same time, the combination therapy using chloroquine and azithromycin caused a critical prolongation of the QT interval in some cases. On 4 July 2020, WHO accepted the Solidarity Trial’s International Steering Committee recommendation has stop the trial of these drugs. Cardiologists should review the latest information on the effects of coronavirus on the cardiovascular system and based on this, make recommendations the management and treatment of severe patients.
Keywords
Full Text
About the authors
V N Oslopov
Kazan State Medical University
Email: kostya_s99@mail.ru
Russian Federation, Kazan, Russia
J V Oslopova
Kazan (Volga Region) Federal University
Email: kostya_s99@mail.ru
Russian Federation, Kazan, Russia
E V Hazova
Kazan State Medical University
Email: kostya_s99@mail.ru
Russian Federation, Kazan, Russia
K S Sergienko
Kazan State Medical University
Author for correspondence.
Email: kostya_s99@mail.ru
Russian Federation, Kazan, Russia
A F Murzakhanova
Kazan State Medical University
Email: kostya_s99@mail.ru
Russian Federation, Kazan, Russia
J M Boichuk
Kazan State Medical University
Email: kostya_s99@mail.ru
Russian Federation, Kazan, Russia
References
- Stokes E.K., Zambrano L.D., Anderson K.N. et al. Coronavirus disease 2019 case surveillance — United States, January 22 — May 30, 2020. MMWR Morb. Mortal. Wkly. Rep. 2020; 69; 759–765. doi: 10.15585/mmwr.mm6924e2.
- Kuba K., Imai Y., Rao S. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005; 11 (8): 875–879. doi: 10.1038/nm1267.
- Vardanyan Ya.T. COVID-19 and increased risk of ventricular arrhythmias in patients with long QT syndrome). Molodoy uchenyy. 2020; (14): 99–102. (In Russ.)
- Khashkhusha T.R., Chan J.S.K., Harky A. ACE inhibitors and COVID-19: We don't know yet. J. Card. Surg. 2020; 35 (6): 1172–1173. doi: 10.1111/jocs.14582.
- Greber U.F., Singh I., Helenius A. Mechanisms of virus uncoating. Trends Microbiol. 1994; 2 (2): 52–56. doi: 10.1016/0966-842x(94)90126-0.
- Oslopova Yu.V., Oslopov V.N. Ekstrasistoliya (sostoyanie problemy, membrannye aspekty patogeneza i lecheniya). (Extrasystole (state of the problem, membrane aspects of pathogenesis and treatment).) Monograph. Kazan: Meddok. 2012; 300 p. (In Russ.)
- published online ahead of print, 2020 Mar 31 doi: 10.1016/j.hrthm.2020.03.024.
- Zhou D., Dai S.M., Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J. Antimicrob. Chemother. 2020; 75 (7): 1667–1670. doi: 10.1093/jac/dkaa114.
- White N.J. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 2007; 7 (8): 549–558. doi: 10.1016/S1473-3099(07)70187-1.
- Liu J., Cao R., Xu M. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6: 16. doi: 10.1038/s41421-020-0156-0.
- Ramireddy A., Chugh H., Reinier K. et al. Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: Implications for QT interval monitoring. J. Am. Heart Assoc. 2020; 9 (12): e017144. doi: 10.1161/JAHA.120.017144.
- Mitra R.L., Greenstein S.A., Epstein L.M. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. Heart Rhythm. Case Rep. 2020; 6 (5): 244–248. doi: 10.1016/j.hrcr.2020.03.016.
- Kolotsei L.V., Snezhitskiy V.A., Ardashev A.V. Coronavirus disease (COVID-19) treatment algorithms in patients with QT interval prolongation. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta. 2020; 18 (2): 203–210. (In Russ.) doi: 10.25298/2221-8785-2020-18- 2-203-210.
- Shlyakhto E.V., Konradi A.O., Villeval'de S.V. et al. Rukovodstvo po diagnostike i lecheniyu bolezney sistemy krovoobrashcheniya (BSK) v kontekste pandemii COVID-19 (kratkaya versiya). (Guidelines for the diagnosis and treatment of circulatory system disorders (CVD) in the context of the COVID-19 pandemic (short version).) 2020; 10. https://scardio.ru/content/Guidelines/COVID-19.pdf (access date: 15.08.2020). (In Russ.)
- Sapp J.L., Alqarawi W., MacIntyre C.J. et al. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: A statement from the Canadian Heart Rhythm Society. Can. J. Cardiol. 2020; 36 (6): 948–951. doi: 10.1016/j.cjca.2020.04.003.
Supplementary files
